Clinical Characteristics and Survival of Patients with Hairy Cell Leukemia Treated at the National Cancer Institute in Peru from 1999 to 2018

被引：0
|
作者：
Pena, Estefania [1 ]
Vasquez, Jule [1 ]
机构：
[1] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
HCL; hairy cell leukemia; cladribine; rituximab; survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-057
引用
下载
收藏
页码：S399 / S400
页数：2
相关论文
共 50 条
  • [21] Characteristics of patients with non-small cell lung cancer at the National Cancer Institute of Colombia
    Cardona, Andres F.
    Arrieta, Oscar
    Ruiz-Patino, Alejandro
    Rojas, Leonardo
    Rolfo, Christian
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2021, 25 (04): : 225 - 230
  • [22] Characteristics of patients with non-small cell lung cancer at the National Cancer Institute of Colombia
    Alarcon, Martha-Liliana
    Bruges, Ricardo
    Carvajal, Carlos
    Vallejo, Camilo
    Beltran, Rafael
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2021, 25 (02): : 103 - 109
  • [23] CLINICAL CHARACTERISTICS AND SURVIVAL IN PEDIATRIC PATIENTS WITH DIAGNOSIS OF PARAMENINGEAL RHABDOMYOSARCOMA AT THE NATIONAL INSTITUTE OF PEDIATRICS (INP). MEXICO
    Cardenas, Rocio
    Velasco-Hidalgo, Liliana
    Bellido-Magana, Rosalba
    Rivera-Luna, Roberto
    Gonzalez-Garay, Alejandro
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 792 - 792
  • [24] Prognostic factors of survival in patients with Burkitt lymphoma treated at the National Institute of Neoplastic Diseases in Peru: A 14-years' experience.
    Solf, Rossana
    Aliaga, Rolig
    Vallenas, Francisco
    Flores, Claudio J.
    Malpica, Luis
    Chavez, Jule Franve Vasquez
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Survival of stage III colon cancer patients with adjuvant chemotherapy: Experience from a specialized cancer institute in Latinoamerica - Peru
    Veramendi Cabana, Eder Christian
    Cotito Izquierdo, Jorge Antonio
    Macetas, Jackeline
    Serrano, Mariana
    Pacheco, Cristian
    Castro, Victor
    Araujo, Jhajaira M.
    Catherine Montenegro, Paola
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016 (vol 8, pg 2942, 2019)
    Ylescas-Soria, J.
    de la Torre-Lujan, A. H.
    Herrera, L. A.
    CANCER MEDICINE, 2020, 9 (05): : 1951 - 1951
  • [27] Global survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiotherapy (IMRT) at the National Cancer Institute
    Jimenez Cotes, Adriana
    Alejandro Esguerra, Jose
    Morales-Ramirez, Laura
    Norena, Paulina
    Ballesteros, Holman
    Isabel Cotes, Martha
    Gonzales, Garvin
    Rugeles, Jorge
    Manuel Hoyos, Luis
    Ospino-Pena, Rosalba
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2020, 24 (04): : 157 - 163
  • [28] EPIDEMIOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF CHILDREN WITH MEDULLOBLASTOMA TREATED AT THE NATIONAL CANCER INSTITUTE (INCA) IN RIO DE JANEIRO, BRAZIL
    Oigman, Gabriela
    Osorio, Diana
    Stanek, Joseph
    Finlay, Jonathan
    Vianna, Denizar
    Ferman, Sima
    NEURO-ONCOLOGY, 2020, 22 : 384 - 384
  • [29] Epidemiological characteristics and survival outcomes of children with medulloblastoma treated at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil
    Oigman, Gabriela
    Osorio, Diana S.
    Ferman, Sima
    Stanek, Joseph R.
    Aversa do Souto, Antonio
    Christiani, Marcio M. C.
    Magalhaes, Denise M. A.
    Finlay, Jonathan L.
    Vianna, Denizar A.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (01)
  • [30] Incidence and survival of Hodgkin lymphoma patients treated at a national cancer center in a middle-income country from 1999-2018: A report of 1,382 cases.
    Chavez, Jule Franve Vasquez
    Zapata, Arturo
    Garcia, Juan Luis
    Barrionuevo, Carlos
    Diaz, Edgar
    Poquioma, Ebert
    Vidaurre, Tatiana
    Malpica, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345